Defining eligible patients for allele-selective chemotherapies targeting NAT2 in colorectal cancer
Verónica Rendo(Uppsala University), Tobias Sjöblom(Uppsala University)
Cited by 7
Related Papers
Loss of DIP2C in RKO cells stimulates changes in DNA methylation and epithelial-mesenchymal transition
|BMC Cancer|2017|42
Exploiting loss of heterozygosity for allele-selective colorectal cancer chemotherapy
|Nature Communications|2020|24
Linking FOXO3, NCOA3, and TCF7L2 to Ras pathway phenotypes through a genome-wide forward genetic screen in human colorectal cancer cells
|Genome Medicine|2018|10
A compendium of Amplification-Related Gain Of Sensitivity (ARGOS) genes in human cancer
|bioRxiv (Cold Spring Harbor Laboratory)|2023|2